Description
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis) | HTML | https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin.html | |
| Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis) | HTML | https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/examens-innocuite/resume-examen-innocuite-inhibiteurs-sglt2-canagliflozine-dapagliflozine-empagliflozine-evaluation-risque.html |